



Biotech Daily

Wednesday March 2, 2022

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: MEDICAL DEVELOPMENTS UP 32%;
- NOVA EYE DOWN 9%**
- * **ANTERIS '20% DISCOUNT' \$28m PLACEMENT; PERCEPTIVE TAKES 14%**
- * **MEDIBIO, CPS: 'UKRAINE WAR ENDS UNDERWRITING'**
- * **TELIX 'MARKET CONDITIONS' CANCEL SHARE PLAN**
- * **MEDICAL DEVELOPMENTS: FDA LIFTS CLINICAL HOLD ON PENTHROX**
- * **CARDIEX: MOBVOI TICWATCH WITH ATCOR TECHNOLOGY**
- * **ADALTA: CHINA PATENT FOR AD-214**
- * **MITSUBISHI TAKES 6.7% OF NANOSONICS**
- * **REGENEUS LOSES DIRECTOR DR JOHN CHIPLIN**
- * **MEDIBIO APPOINTS DR MATT MESNIK DIRECTOR**

MARKET REPORT

The Australian stock market was up 0.28 percent on Wednesday March 2, 2022, with the ASX200 up 20.2 points to 7,116.7 points. Thirteen of the Biotech Daily Top 40 stocks were up, 21 fell, five traded unchanged and one was untraded.

Medical Developments was the best, up \$1.08 or 31.7 percent to \$4.49, with 911,210 shares traded. Cyclopharm and Dimerix climbed eight percent or more; Polynovo was up 7.3 percent; Amplia, Cynata, Micro-X and Universal Biosensors improved more than three percent; Next Science and Prescient rose more than two percent; Compumedics, Immutep, Patrys and Resmed were up more than one percent; with Cochlear up 0.1 percent.

Nova Eye led the falls, down 2.25 cents or 9.1 percent to 22.5 cents, with 25,689 shares traded. Antisense and Paradigm lost more than six percent; Avita, Clinuvel, Imugene and Opthea were down more than five percent; Mesoblast and Pharmaxis fell more than four percent; Actinogen, Atomo and Impedimed were down more than three percent; Alcidion, Nanosonics, Oncosil and Starpharma shed more than two percent; Orthocell lost 1.2 percent; with CSL, Emvision, Genetic Signatures, Neuren and Pro Medicus down by less than one percent.

ANTERIS TECHNOLOGIES

Anteris says it has raised \$27,600,00 through a placement at \$15.00 a share to New York's Perceptive Advisors, which has become a 14 percent largest shareholder.

Anteris said 1,840,000 shares were priced at a 20 percent discount to the closing price on February 28, 2022, and the proceeds would be used for the clinical development of its Duravr three-dimensional, single-piece aortic valve for aortic stenosis.

Anteris said it would start a US phase II study of Duravr in patients with aortic stenosis this year, and a European trial for a potential Conformité Européenne (CE) mark filing in 2023. Anteris was up 33 cents or 1.8 percent to \$19.00.

MEDIBIO (FORMERLY BIOPROSPECT)

Medibio says it and CPS Capital "have mutually agreed that the [underwriting] agreement be terminated in light of the escalation of hostilities between Russia and Ukraine".

Last December, Medibio said it hoped to raise \$5.7 million through a \$2.25 million placement at 0.5 cents a share and a \$3.4 million one-for-three rights offer at the same price, with the entitlement offer, pending shareholder approval, expected to be underwritten with the underwriting terms "yet to be finalized" (BD: Dec 15, 2021).

In January, Medibio said its \$3.4 million rights offer would be underwritten to \$1 million by CPS Capital Group Pty Ltd, which would have the ability to place the shortfall, for a fee of \$20,000 and six percent of the underwritten \$1 million and any shortfall placed. According to Commsec data, throughout February, Medibio has traded around 0.4 cents a share, falling as low as 0.3 cents a share.

Today, the company said that it and CPS "mutually agreed that the agreement be terminated in light of the escalation of hostilities between Russia and Ukraine".

Medibio said it would work with CPS "on a best endeavors to place any shortfall of the entitlement offer in the three month period after the close of the ... offer" and with its share registry was working towards offering withdrawal rights to those shareholders who have already subscribed to the entitlement offer.

Biotech Daily attempted to contact both Medibio and CPS Capital to ask what the Russia-Ukraine conflict had to do with the entitlement offer.

CPS Capital managing-director Jason Peterson referred Biotech Daily to Medibio, but Medibio had not responded at the time of publication.

Prior to acquiring its Invatec heart rate-for-depression technology, the then Bioprospect had been involved with the now delisted Solagran, which was attempting to commercialize Siberian pine needle extracts for Alzheimer's disease, hepatitis, liver cancer and veterinary purposes (BD: Apr 14, Nov 25, Dec 8, 2014; Mar 6, 2015).

Medibio fell 0.05 cents or 12.5 cents to 0.35 cents with 1.4 million shares traded.

TELIX PHARMACEUTICALS

Telix says it has cancelled its share plan at \$7.70 a share "after considering current market conditions, which have changed significantly in recent weeks".

According to Commsec data, for most of February, Telix traded below \$7.00 a share.

In January, the company said it had raised \$175 million in a placement at \$7.70 a share, a 4.8 percent discount to the January 1, 2022 closing price, and hoped to raise \$25 million more through a share plan (BD: Jan 24, 2022).

Today, the company said the decision did not affect the completed placement and it had "no current intention to undertake a new share purchase plan.

Telix was unchanged at \$5.16 with 1.96 million shares traded.

MEDICAL DEVELOPMENTS INTERNATIONAL

Medical Developments says the US Food and Drug Administration has lifted its clinical hold on its Pentrox inhaled analgesic, allowing a 200-patient, phase III trial to begin.

In 2018, Medical Developments said its US program was on hold pending a series of questions from the US Food and Drug Administration (BD: Jul 25, Aug 29, 2018).

The company's "green whistle" methoxyflurane inhaled analgesic has been used in Australian ambulance for more than 20 years, and has been approved in Europe and Canada.

Today, the company said the FDA had "unconditionally lifted ... [its] clinical hold on Pentrox".

Medical Developments said the two-year, phase III trial would be conducted on a targeted trauma and associated pain patient group, with recruitment to begin "in late 2022".

Medical Developments chair Gordon Naylor said the news was "important as it brings Pentrox a step closer to licensure in the US market and because the FDA is seen as a global regulatory leader".

Medical Developments was up \$1.08 or 31.7 cents to \$4.49 with 911,210 shares traded.

CARDIEX

Cardiex says Mobvoi has launched the Ticwatch GTH Pro, using subsidiary Atcor's advanced cardiac health features.

Cardiex said the Beijing-based Mobvoi was a consumer electronics manufacturer and the Ticwatch would include the Atcor Arty Heart Health analytics platform, based on Atcor's US Food and Drug Administration-cleared Sphygmocor technology.

The company said the Arty platform provided an overall measure of heart and arterial health, as well as a range of other cardiac health indicators.

Cardiex managing-director Craig Cooper said the launch was "the first integration of our market-leading Sphygmocor heart health technology into a wearable device and has been the result of a significant two-year collaboration with Mobvoi".

"Our Arty Heart Health platform incorporates unique arterial biometrics and heart health insights based on the 20-year legacy of our Atcor subsidiary in partnering with global research organizations, pharmaceutical companies and leading clinical practices," Mr Cooper said.

"The Ticwatch GTH Pro is the first in a number of new consumer product releases planned for this year as we continue to move forward with the development, FDA clearance process, and launch of a suite of new wearable and home health devices and apps under our new Conneqt brand," Mr Cooper said.

The company said the product would be available through Mobvoi's website and Amazon. Cardiex fell 1.5 cents or 2.9 cents to 50 cents.

ADALTA

Adalta says the China National Intellectual Property Administration has granted a patent protecting its lead drug candidate AD-214.

Adalta said that the patent, titled 'CXCR4 binding molecules' would protect the antibody sequence used in AD-214, as well as derivatives containing the sequence, until January 8, 2036.

The company said patents had been granted in Australia, the US, Japan and Singapore. Adalta was up fell 0.1 cents or 1.3 cents to 7.6 cents.

[NANOSONICS](#)

Mitsubishi UFJ Financial group and related subsidiaries say they have become substantial in Nanosonics with 20,270,153 shares or 6.72 percent of the company.

The Tokyo-based Mitsubishi said that in more than 4,000 trades between October 25, 2021 and February 24, 2022, it bought and transferred shares.

Nanosonics fell 10 cents or 2.3 cents to \$4.25 with 780,644 shares traded.

[REGENEUS](#)

Regeneus says Dr John Chiplin has resigned as a non-executive director, effective immediately.

Regeneus said Dr Chiplin was appointed a director in April 2019.

Regeneus was untraded at 6.6 cents.

[MEDIBIO](#)

Medibio says it has appointed Dr Matt Mesnik as a non-executive director, effective immediately.

Medibio said Dr Mesnik was previously its chief medical officer and was currently the chief medical officer of Spok, “a clinical communication and collaboration company serving more than 2,200 hospitals in the US, Australia and Canada”, as well as being an adviser to Igan Partners, Canada’s largest health technology venture capital fund.

The company said that Dr Mesnik had worked as a chief medical officer for Aprima Medical Software, Sanso, Ativa Medical, Vigilant Diagnostics and Quick Check Health.